Study Links Proteins, Heart Disease

JUNE 01, 2005

Johns Hopkins University has published the first study to establish a link between proteins and heart disease. Lipoprotein a and apolipoprotein a, also known as Lp(a) and apo(a), are cholesterol-carrying proteins and may now be used as predictors of cardiovascular problems.

Researchers monitored 833 dialysis patients for 2 years and found that those with high levels of Lp(a) had a 38% higher risk of heart disease. Patients whose apo(a) particles were of the smallest size had a 58% higher risk of heart disease. For those patients with both high levels of Lp(a) and the smallest size particles of apo(a), an even greater risk of heart disease existed-73%. The results of this study, which were published in the Journal of the American Society of Nephrology, demand further research to determine what effect adjusting these levels and sizes will have on the risk of cardiovascular problems.



SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.